Ramosetron

Ramosetron
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		By mouth (ODT), IV
ATC code
  • None
Pharmacokinetic data
Elimination half-life5.8 hours
Identifiers
IUPAC name
  • (1-Methyl-1H-indol-3-yl)[(5R)-4,5,6,7-tetrahydro-1H-benzimidazol-5-yl]methanone
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H17N3O
Molar mass279.343 g·mol−1
3D model (JSmol)
SMILES
  • CN1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4
InChI
  • InChI=1S/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)/t11-/m1/s1 ☒N
  • Key:NTHPAPBPFQJABD-LLVKDONJSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Ramosetron (INN) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting.[1] Ramosetron is also indicated for a treatment of "diarrhea-predominant irritable bowel syndrome in male and women".[2] In India it is marketed under the brand name of Ibset.

It is only licensed for use in Japan and selected Southeast Asian countries. In Japan it is sold under the trade name Irribow.[3][4] and in India as Ibset . 'Elsewhere it is commonly sold under the trade name Nasea and in India as Nozia (150 μg/mL injection & 100 μg oral tablet).[5]

References

  1. ↑ Fujii Y, Saitoh Y, Tanaka H, Toyooka H (February 2000). "Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery". Anesth. Analg. 90 (2): 472–5. doi:10.1097/00000539-200002000-00043. PMID 10648342.
  2. ↑ "2008 News Releases - Astellas Pharma Inc". www.astellas.com.
  3. ↑ Summary in Japanese. Retrieved on September 4, 2012.
  4. ↑ "2013 News Releases | Astellas Pharma Inc". www.astellas.com. Retrieved 2018-04-06.
  5. ↑ Abridged prescribing information — Nasea (MIMS Philippines). Retrieved on June 13, 2008.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.